| 0 (0%) | 09-27 13:01 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 30.73 | 1-year : | 32.17 |
| Resists | First : | 26.31 | Second : | 27.54 |
| Pivot price | 25.94 |
|||
| Supports | First : | 24.31 | Second : | 20.23 |
| MAs | MA(5) : | 26.5 |
MA(20) : | 25.88 |
| MA(100) : | 26.42 |
MA(250) : | 28.66 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 54.2 |
D(3) : | 70.1 |
| RSI | RSI(14): 49.2 | |||
| 52-week | High : | 35.93 | Low : | 21.92 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CHX ] has closed above bottom band by 46.0%. Bollinger Bands are 5.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.82 - 25.95 | 25.95 - 26.08 |
| Low: | 25.5 - 25.64 | 25.64 - 25.78 |
| Close: | 25.6 - 25.81 | 25.81 - 26.02 |
Mon, 01 Sep 2025
cross-coupling on copper alloy catalysts with engineered oxygen affinity - Nature
Thu, 28 Aug 2025
Sc]Sc-CHX-A″-DTPA-RCCB6: A PET Tracer for Imaging CD70 Expression Across Latency Types of Burkitt Lymphoma - Journal of Nuclear Medicine
Thu, 17 Jul 2025
SLB stock rises as UBS reiterates Buy rating following CHX acquisition - Investing.com
Wed, 16 Jul 2025
SLB Completes Acquisition of ChampionX - SLB
Tue, 15 Jul 2025
SLB's ChampionX deal clears final hurdle with UK approval - Reuters
Tue, 17 Jun 2025
Human Fc CH2 domain modifies cholix transcytosis pathway to facilitate efficient oral therapeutic protein delivery - ScienceDirect.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 191 (M) |
| Shares Float | 189 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 95.5 (%) |
| Shares Short | 4,500 (K) |
| Shares Short P.Month | 4,490 (K) |
| EPS | 1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.01 |
| Profit Margin | 8.1 % |
| Operating Margin | 14.4 % |
| Return on Assets (ttm) | 9.4 % |
| Return on Equity (ttm) | 16.8 % |
| Qtrly Rev. Growth | -6.4 % |
| Gross Profit (p.s.) | 6.21 |
| Sales Per Share | 18.7 |
| EBITDA (p.s.) | 3.97 |
| Qtrly Earnings Growth | -24.2 % |
| Operating Cash Flow | 483 (M) |
| Levered Free Cash Flow | 253 (M) |
| PE Ratio | 17.09 |
| PEG Ratio | 0 |
| Price to Book value | 2.57 |
| Price to Sales | 1.38 |
| Price to Cash Flow | 10.23 |
| Dividend | 0.09 |
| Forward Dividend | 0 |
| Dividend Yield | 0.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|